Attana

0.006

SEK

0 %

Less than 1K followers

ATANA

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

0%

0%

0%

-71.43%

-86.53%

-85.42%

-98.29%

-97.51%

-96.1%

Attana conducts research and development of pharmaceuticals. The company specialises in vitro characterization of molecular interactions, which is used for analysis in the development of new pharmaceuticals. The company's patented solutions are mainly used in the study of different binding properties and macrostructures in cells, proteins, viruses, and bacteria. Operations are found mainly within the Nordic countries and Europe. The company was established in 2002 is based in Stockholm.

Market cap

8.28M SEK

Turnover

50.52K SEK

Revenue

4.1M

EBIT %

-244.15 %

P/E

-

Dividend yield-%

-

Financial calendar

9.5

2025

Interim report Q1'25

9.5

2025

General meeting '25

22.8

2025

Interim report Q2'25

All

Press releases

ShowingAll content types

Press release4/30/2024, 9:45 AM

BioInvent evaluating Attana Technology

Press release4/25/2024, 1:43 PM

Attana enters the third year of a five-year service and support contract with a leading health institute in the US

Press release4/1/2024, 9:29 AM

New paper using Attana tecnology to understand how viruses enter human cells

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release3/5/2024, 9:44 AM

Attana: One of US leading health institutes has placed an order for an upgrade of an existing instrument, valued at $150k

Press release2/13/2024, 2:14 PM

New paper using Attana Technology to study structures on surface in Ion Liquids demonstrating the effect of surface charges on interaction properties.

Press release1/23/2024, 12:42 PM

New publication using Attana technology towards environmentally friendly and financially viable methods to create functional materials

Press release12/20/2023, 7:30 AM

New article using Attana's technology from National University of Singapore: Immunity differences in vaccinated individuals according to age, gender, lifestyle and other diseases

Press release12/18/2023, 7:30 AM

Attana: Biosensors to characterize immune response to bacterial diseases

Press release12/5/2023, 10:15 AM

Attana and Linnaeus University have published the first part of the science behind immunity profiles

Press release12/4/2023, 8:56 AM

Attana: Breakthrough order with new customer in the USA

Press release11/23/2023, 7:28 AM

Attana: Strengthened collaboration with European biotech customer who extends their service and support agreement for another 12 months.

Press release11/20/2023, 10:55 AM

A new publication using Attana Technology from National University of Singapore examining the neutralization capacity of human IgG antibodies agsinst different mutations of the SARS-CoV-2

Press release11/15/2023, 1:51 PM

Attana: Robust QCM-Based Sensing and Assay Formats in Commercialized Systems

Press release10/4/2023, 3:03 PM

Attana: Dear shareholders and valuable followers,

Press release9/26/2023, 9:33 AM

New publication that shows the strength of Attana's offering in diagnostics, here applied in veterinary medicine.

Press release9/6/2023, 1:14 PM

New publication from National University of Singapore using Attana Technology to study Immune Response from Tuberculosis Exposed Healthy Individuals

Press release8/28/2023, 3:32 PM

The Swedish Knowledge-Foundation has granted SEK 12 million to a project concerning individual immunity profiles for diagnostics and medical development based on Attana's QCM technology.

Press release5/30/2023, 8:41 AM

Education in advanced Attana cell-based assays and practical hands-on training in maintenance.

Press release5/23/2023, 7:23 AM

Attana prolongs service and support contract with European client

Press release5/23/2023, 6:06 AM

Attanas immunity profiles depicted in the Life Science section of yesterday's Dagens Nyheter

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.